ESC 2021 The 2021 guidelines on CVD prevention in clinical practice contain recommendations at the individual and the population level. New at the individual level is a stepwise approach to intensify preventive treatments.
ESC 2021 Prof. Anker talks about the rationale, design, results and implications of the EMPEROR-Preserved trial which investigated the efficacy and safety of the SGLT2 inhibitor empagliflozin in patients with HFpEF.
ESC 2021 Two recent trials with fish oil, the REDUCE-IT trial and the STRENGTH trial, have shown conflicting results. How should we interpret these findings? Several lipid experts go through the evidence and provide their views.
ESC 2021 The Salt Substitute and Stroke Study (SSaSS) showed that replacement of salt (100% NaCl) with a salt substitute (75% NaCl + 25% KCl) reduces the risk of stroke in people with prior stroke or hypertension.
ESC 2021 Prof. Bruce Neal discusses the results of the SSaSS study which showed that replacing dietary salt with a salt substitute reduced stroke, CV events and death, without increasing the risk of hyperkalemia.
ESC 2021 Prof. Carolyn Lam discusses the major changes in the 2021 ESC/HFA heart failure guidelines regarding diagnosis and treatment of patients with ejection fraction above 40%.
ESC 2021 The EMPEROR-Preserved trial showed that empagliflozin significantly reduced the risk of the primary composite endpoint of CV death or HF hospitalization by 21%, compared to placebo, in patients with HF and LVEF >40%, with and without T2DM.
ESC 2021 FIDELITY was a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, which showed that finerenone reduced the risk of CV and renal outcomes in patients with T2DM and mild-to-severe CKD.
ESC 2021 New concepts in the 2021 HF guidelines include a simplified treatment algorithm for HFrEF, change of the HFmrEF term to heart failure with mildly reduced ejection fraction and a treatment algorithm for HFrEF according to phenotypes.
ESC 2021 EMPEROR-Pooled was a pooled analysis of the data from EMPEROR-Reduced and EMPEROR-Preserved and showed that empagliflozin, compared to placebo, reduced HF hospitalizations by ~30% in patients with HF across a range of LVEF from <25% to <65%.